Apricoxib: Difference between revisions

Apricoxib
Identifiers
	IUPAC name 4-[2-(4-Ethoxyphenyl)-4-methyl-1H-pyrrol-1-yl]benzenesulfonamide;
CAS Number	162011-90-7;
PubChem CID	9820073;
ChemSpider	7995822;
CompTox Dashboard (EPA)	DTXSID60173502 ;
Chemical and physical data
Formula	C19H20N2O3S
Molar mass	356.4387 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCOC1=CC=C(C=C1)C2=CC(=CN2C3=CC=C(C=C3)S(=O)(=O)N)C;

Browse history interactively

← Previous edit Next edit →

Content deleted Content added

VisualWikitext

Inline

Revision as of 12:23, 10 July 2014

Apricoxib is an experimental anticancer drug in Phase II clinical trials. It is a COX-2 inhibitor which improves standard therapy response in molecularly defined models of pancreatic cancer.^[1]

References

^ Attention: This template ({{cite doi}}) is deprecated. To cite the publication identified by doi:10.1158/1078-0432.CCR-12-0453, please use {{cite journal}} (if it was published in a bona fide academic journal, otherwise {{cite report}} with |doi=10.1158/1078-0432.CCR-12-0453 instead.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[1] Attention: This template ({{cite doi}}) is deprecated. To cite the publication identified by doi:10.1158/1078-0432.CCR-12-0453, please use {{cite journal}} (if it was published in a bona fide academic journal, otherwise {{cite report}} with |doi=10.1158/1078-0432.CCR-12-0453 instead.

[1]

@@ Line 1: / Line 1: @@
-Apricoxib, a novel [[COX-2 inhibitor]], markedly improves standard therapy response in molecularly defined models of pancreatic cancer.<ref>{{Cite doi|10.1158/1078-0432.CCR-12-0453}}</ref>
 {{Drugbox
 | verifiedrevid =
-| IUPAC_name = 4-[2-(4-Ethoxyphenyl)-4-methyl-1H-pyrrol-1-yl]benzenesulfonamide
+| IUPAC_name = 4-[2-(4-Ethoxyphenyl)-4-methyl-1''H''-pyrrol-1-yl]benzenesulfonamide
 | image = Apricoxib_structure.svg
@@ Line 28: / Line 26: @@
 | StdInChIKey =
 }}
+'''Apricoxib''' is an experimental anticancer drug in Phase II clinical trials. It is a [[COX-2 inhibitor]] which improves standard therapy response in molecularly defined models of pancreatic cancer.<ref>{{Cite doi|10.1158/1078-0432.CCR-12-0453}}</ref>
 ==See also==
 *[[Tilmacoxib]]
 *[[cimicoxib]]
-*[[SC 57666]]
 *[[NS-398]]
 *[[Celecoxib]]
@@ Line 39: / Line 38: @@
 {{reflist}}
-[[Category:Non-steroidal anti-inflammatory drugs]]
 [[Category:COX-2 inhibitors]]
 [[Category:Sulfonamides]]
-{{musculoskeletal-drug-stub}}
+{{pharma-stub}}